Frontlight ResearchEarly access
Metastatic breast cancer trials in China
224 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleUtidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer
- Where
- Zhengzhou
- Age
- 18 years to 70 years
- People
- 79
- Run by
- Henan Cancer Hospital
See details and how to joinNCT05398861 - Phase 2Taking peopleA Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates
- Where
- Guangzhou
- Age
- 18 years and over
- People
- 52
- Run by
- Sun Yat-sen University
See details and how to joinNCT07520760 - Phase 1/2Taking peopleDual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
- Where
- Shenzhen
- Age
- 18 years to 75 years
- People
- 60
- Run by
- Beijing Biotech
See details and how to joinNCT07510802 - Phase 1/2Taking peopleA Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
- Where
- Chengdu, Dalian
- Age
- 18 years to 75 years
- People
- 180
- Run by
- Shandong Suncadia Medicine Co., Ltd.
See details and how to joinNCT07389733 - No phaseTaking peopleReal-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China
- Where
- Bingjie
- Age
- 18 years to 99 years
- People
- 14,000
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07476170 - Phase 2Taking peopleStudy of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
- Where
- Zhengzhou
- Age
- 18 years to 75 years
- People
- 150
- Run by
- Henan Cancer Hospital
See details and how to joinNCT05769010 - Phase 3Taking peopleA Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
- Where
- Beijing, Harbin
- Age
- 18 years to 75 years
- People
- 640
- Run by
- InventisBio Co., Ltd
See details and how to joinNCT06954961 - Phase 2Taking peopleEfficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
- Where
- Beijing, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Linyi, Nanjing, Shanghai, Tianjin, Wuhan
- Age
- 18 years and over
- People
- 94
- Run by
- TransThera Sciences (Nanjing), Inc.
See details and how to joinNCT07498478 - Phase 3Taking peoplePrecise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
- Where
- Shanghai
- Age
- 18 years to 70 years
- People
- 134
- Run by
- Fudan University
See details and how to joinNCT05806060 - Phase 2/3Taking peopleA Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
- Where
- Beijing
- Age
- 18 years and over
- People
- 706
- Run by
- Shanghai Henlius Biotech
See details and how to joinNCT07294508 - Phase 1/2Taking peopleDual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
- Where
- Shenzhen
- Age
- 18 years to 75 years
- People
- 60
- Run by
- Beijing Biotech
See details and how to joinNCT07486089 - Phase 2Taking peopleStudy on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 45
- Run by
- Fudan University
See details and how to joinNCT07471776 - Phase 3Taking peopleDalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment
- Where
- Fuzhou
- Age
- 18 years and over
- People
- 258
- Run by
- Fujian Cancer Hospital
See details and how to joinNCT07467330 - No phaseTaking peopleA Study on the Efficacy and Safety of Switching Between Two Targeted Strategies, HP+Chemotherapy and HPy+Chemotherapy, After Treatment Progression in HER-2 Positive Advanced or Metastatic Breast Cancer
- Where
- Zhejiang
- Age
- 18 years and over
- People
- 600
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT07455188 - Phase 2Taking peopleDisitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
- Where
- Nanjing
- Age
- 18 years to 75 years
- People
- 37
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07446452 - Phase 1/2Taking peopleA Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients
- Where
- Harbin, Zhengzhou
- Age
- 18 years to 75 years
- People
- 300
- Run by
- Shandong Suncadia Medicine Co., Ltd.
See details and how to joinNCT06679036 - Phase 3Taking peopleIBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
- Where
- Beijing
- Age
- 18 years and over
- People
- 540
- Run by
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
See details and how to joinNCT07377643 - Phase 2Not yet taking people in ChinaPhase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)
- Where
- Beijing
- Age
- 18 years and over
- People
- 78
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07413601 - No phaseTaking peopleReal-world Studies of CDK4/6 Inhibitors
- Where
- Tianjin
- Age
- 18 years and over
- People
- 245
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07407439 - Phase 2Taking peopleResponse-Based Local Therapy for Regionally Advanced Breast Cancer
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 157
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07376538 - Phase 1/2Taking peopleA Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
- Where
- Changchun, Chengdu, Guangzhou, Hangzhou, Hefei, Huizhou, Jinan, Luoyang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Wuhan, Xinxiang, Yibin, Yongzhou, Zhengzhou
- Age
- 18 years and over
- People
- 99
- Run by
- Forward Pharmaceuticals Co., Ltd.
See details and how to joinNCT06064812 - Phase 2Taking peoplectDNA-guided Treatment Decision-making
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 122
- Run by
- Fudan University
See details and how to joinNCT07394218 - No phaseTaking peopleDalpiciclib in HR+/HER2- ABC
- Where
- Shanghai
- Age
- 18 years and over
- People
- 103
- Run by
- RenJi Hospital
See details and how to joinNCT06301438 - Phase 1/2Taking peopleTarget-specific immunoPET Imaging of Breast Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 200
- Run by
- RenJi Hospital
See details and how to joinNCT06715826 - Phase 2Enrolling by invitationSacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC
- Where
- Beijing
- Age
- 18 years and over
- People
- 60
- Run by
- YING FAN
See details and how to joinNCT07359404